Cibus (CBUS) Stock Price

Cibus Price

NASDAQ·CLOSED
1.31
​
Market closed

Revenue has compounded at 11.1% per year over the past 10 years to 3.64 M USD. Cibus's net margin stands at -3,492.3%, down from -112.4% several years earlier.

Cibus stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cibus business model & stock analysis

Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. The company is headquartered in San Diego, California and currently employs 236 full-time employees. The company went IPO on 2017-07-20. The firm is engaged in developing and licensing plant traits to seed companies for royalties on seed sales. The firm is involved in gene-edited trait development, where plant traits (or specific genetic characteristics) that are indistinguishable from traits developed using traditional breeding are created using gene editing. Its patented RTDS technology platform includes the Trait Machine, which is a semi-automated stand-alone trait production facility. The Company’s Trait Machine materially changes the speed, breadth, and scale of trait development. The company is focused on the development of productivity traits and sustainable ingredients. The firm focuses on developing traits for addressing the sustainability challenges presented by climate change, disease, and pests.

Frequently asked questions about Cibus

9 analysts currently rate the Cibus stock: 7 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Cibus to generate revenue of 5.20 M USD and earnings per share of -1.08 USD.

Converted at the current exchange rate, the Cibus share trades at 1.17 EUR (1.31 USD).

The Cibus share (CBUS) is listed on 1 stock exchanges, including: NASDAQ (CBUS).

The expected revenue of Cibus is 5.20 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Cibus is -57.49 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Cibus is currently -1.21. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cibus stock.

The price-to-sales ratio (P/S) of Cibus is currently 13.39. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cibus stock.

The Eulerpool Quality Score for Cibus is 4/10.

The ISIN of Cibus is US17166A1016. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Cibus is CBUS. The ticker symbol is used to trade Cibus shares on the stock exchange.

Fair ValueTerminal
1.13 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
30,838.98 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website calyxt.com
Currency
USD
Initial public offering
Jul 20, 2017
ISIN
US17166A1016
Cusip
17166A101
Market capitalization
88.95 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-1.21
P/Ee 2027
-1.61
P/Ee 2028
-3.20
P/Ee 2029
2.57
P/Ee 2030
0.63
P/Se
13.39
EV/EBIT
—
P/B Ratio
4.07
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-506.56 %
Last updated Oct 20, 2026, 3:27 PM

Cibus Peer Group

Cibus Ticker

NASDAQ · CBUS

Cibus FIGI

CBUS:US · BBG00H1CJS11CBUS:UA · BBG00H1CJS20CBUS:UN · BBG00H1CJS48CBUS:UP · BBG00H1CJS57CBUS:UB · BBG00H1CJS75CBUS:UM · BBG00H1CJS93CBUS:UX · BBG00H1CJSB0CBUS:UR · BBG00H1CJSC9CBUS:UD · BBG00H1CJSH4CBUS:UF · BBG00H1CJSL9CBUS:VY · BBG00H1CJSM8CBUS:VJ · BBG00H1CJSN7

All fundamentals and in-depth analysis of Cibus

Our stock analysis for Cibus stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cibus. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.